FDA Brief

Warning letters Drugs

FDA warning letter to

Altru Telehealth, LLC dba Altru Telehealth

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

What happened

In March 2026, FDA reviewed Altru Telehealth's website and observed that it offered compounded semaglutide and tirzepatide products. FDA found website claims that the compounded drugs were FDA-approved or offered the same results as brand-name drugs, and that the compounding pharmacies were "FDA approved."

What FDA found

  1. The website claimed compounded semaglutide and tirzepatide products were FDA-approved or otherwise evaluated for safety and effectiveness when compounded drugs are not FDA-approved.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website claimed compounded semaglutide and tirzepatide offer the same results as brand-name drugs such as Ozempic, Mounjaro, and Wegovy at a fraction of the cost, which FDA says is false or misleading.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website claimed its compounding pharmacies are "FDA approved," but FDA does not approve or license compounding pharmacies or outsourcing facilities.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. The false or misleading claims cause the compounded drug products to be misbranded and introduced into interstate commerce, which is prohibited.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Altru Telehealth to respond within 15 business days with corrective steps, supporting documents, the entities that produce the compounded products, a sample of labeling, and changes or removal of false or misleading website claims.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies whose products are marketed online
  • marketing and compliance teams for online pharmacy websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low